Sanofi
A global biopharmaceutical company that discovers, develops, and markets medicines and vaccines.
SAN | PA
Overview
Corporate Details
- ISIN(s):
- FR0000120578 (+39 more)
- LEI:
- 549300E9PC51EN656011
- Country:
- France
- Address:
- 46 AVENUE DE LA GRANDE ARMEE, 75017 PARIS
- Sector:
- Manufacturing
Description
Sanofi is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and marketing of therapeutic solutions. The company's portfolio includes a wide range of medicines and vaccines designed to improve human health. Sanofi focuses on several key therapeutic areas, including immunology, oncology, rare diseases, neurology, and vaccines. Emphasizing a research-driven approach, the company increasingly utilizes artificial intelligence to innovate and accelerate the delivery of new treatments for patients worldwide. Sanofi is also a producer of active pharmaceutical ingredients.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2024-09-20 11:30 |
CP : Le tolebrutinib a permis d’allonger de 31 % le délai avant progression con…
|
French | 252.4 KB | ||
| 2024-09-16 18:44 |
Sanofi: Information concerning the total number of voting rights and shares - A…
|
English | 145.2 KB | ||
| 2024-09-16 18:44 |
Sanofi: Informations relatives au nombre de droits de vote et d'actions - AOUT …
|
French | 121.5 KB | ||
| 2024-09-13 18:46 |
6-K
|
English | 75.5 KB | ||
| 2024-09-12 07:00 |
Communiqué de presse : Accord de licence entre Sanofi, RadioMedix et Orano Med …
|
French | 310.8 KB | ||
| 2024-09-11 07:05 |
Press Release: Dupixent phase 3 study confirms significant improvements in itch…
|
English | 221.5 KB | ||
| 2024-09-11 07:05 |
Communiqué de presse : Dupixent : améliorations significatives du prurit et de …
|
French | 212.1 KB | ||
| 2024-09-11 07:00 |
Communiqué de presse : Dupixent est le premier et le seul agent biologique à ob…
|
French | 286.4 KB | ||
| 2024-09-11 07:00 |
Press Release: Dupixent is the first and only biologic to achieve significant i…
|
English | 281.4 KB | ||
| 2024-09-10 17:00 |
Communiqué de presse : Sanofi inaugure la première usine modulable de vaccins e…
|
French | 222.8 KB | ||
| 2024-09-03 16:46 |
6-K
|
English | 29.5 KB | ||
| 2024-09-02 07:00 |
CP- Tolebrutinib satisfait au critère d’évaluation primaire de l’étude de phase…
|
French | 211.2 KB | ||
| 2024-09-02 07:00 |
Press Release: Tolebrutinib meets primary endpoint in HERCULES phase 3 study, t…
|
English | 206.9 KB | ||
| 2024-08-13 15:06 |
SC 13G/A
|
English | 14.4 KB | ||
| 2024-08-13 12:30 |
3
|
English | 6.9 KB |
Automate Your Workflow. Get a real-time feed of all Sanofi filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Sanofi
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Sanofi via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2024-05-02 | N/A | Other | Buy | 71,423 | N/A |
| 2024-04-26 | N/A | Other | Buy | 1,000 | 91,380.00 EUR |
| 2023-06-09 | N/A | Other | Buy | 9 | 856.04 EUR |
| 2023-05-02 | N/A | Other | Buy | 65,205 | 6,364,008.00 EUR |
| 2023-05-02 | N/A | Other | Buy | 500 | 48,835.00 EUR |
Peer Companies
